The STEP 4 trial made it clear: patients who stopped semaglutide after one year regained approximately two-thirds of their lost weight within the following year. The SURMOUNT-4 trial showed similar results for tirzepatide. These findings do not mean GLP-1 medications are not worth taking — they tell us something important about the nature of obesity and weight maintenance that every patient should understand before starting treatment.
Why Weight Regain Happens
Obesity is a chronic, biological condition — not a temporary problem with a fixed endpoint. The hormones and neurological pathways that drive food noise, appetite dysregulation, and energy storage do not permanently reset after weight loss. When GLP-1 medications are discontinued, those biological signals largely return — and so does the hunger, food noise, and appetite that made weight management difficult in the first place.
This is analogous to stopping blood pressure medication — blood pressure typically returns. The medication was managing the underlying biology, not curing it. For many patients, GLP-1 medications are most appropriately considered long-term or indefinite treatment — exactly as statins or antihypertensives are.
That said, patients who use the treatment window wisely — building habits, preserving muscle, resetting their relationship with food — have meaningfully better maintenance outcomes than those who treat the medication as a passive weight loss solution.
What Determines Long-Term Success
- Muscle Preservation During Treatment
Patients who maintain or build muscle while losing weight on GLP-1 medications have a higher resting metabolic rate, which supports weight maintenance after stopping medication. This is the most mechanically important variable for long-term maintenance.
- Habits Built, Not Just Weight Lost
GLP-1 medications create an extraordinary window to build new patterns with food — smaller portions, mindful eating, reduced reactivity to cravings — without the constant hunger that makes these habits impossible off medication. Patients who consciously build these habits during treatment carry something durable forward.
- Continued Exercise
Exercise is perhaps the strongest predictor of long-term weight maintenance in the research literature. Patients who maintain a regular resistance training practice after stopping GLP-1 medications maintain significantly more of their weight loss than sedentary patients.
- Long-Term or Maintenance Dosing
For many patients, the most evidence-based approach is not stopping medication but transitioning to a lower maintenance dose that sustains metabolic benefit while reducing cost. Your provider can discuss whether this is appropriate for your situation.
If You Are Considering Stopping: Do This First
Discuss treatment changes with your provider. The cited withdrawal study did not compare tapering with abrupt discontinuation, so it cannot establish that tapering prevents regain. Topics for an individualized discussion include:
- Whether a change in dose or discontinuation is medically appropriate for your product and circumstances
- A longer maintenance period at your current dose before attempting discontinuation
- Specific protein and exercise targets to establish before stopping
- A clear plan for monitoring weight and metabolic markers after stopping
- A defined threshold (e.g., a specific amount of regain) that would prompt restarting medication